New Vaccines Programmes Optimisation options survey - for EPI, NITAG, national and regional experts

Over 50 new vaccine options have launched in less than a decade — an unprecedented opportunity for governments to optimise routine immunisation:
✅ higher coverage
✅ reduced costs
✅ better cold chain use
✅ stronger supply security

Despite this progress, uptake remains difficult to predict—especially for innovations made in the Global South.

To plan for sustainable supply and affordable prices, we need to understand what drives (and blocks) countries’ vaccine choices.

𝗪𝗲 𝗶𝗻𝘃𝗶𝘁𝗲 𝗶𝗺𝗺𝘂𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗺𝗮𝗸𝗲𝗿𝘀 𝗮𝗻𝗱 𝗮𝗱𝘃𝗶𝘀𝗼𝗿𝘀 𝗶𝗻 𝗺𝗶𝗱𝗱𝗹𝗲, 𝗹𝗼𝘄𝗲𝗿-𝗺𝗶𝗱𝗱𝗹𝗲, 𝗮𝗻𝗱 𝗹𝗼𝘄-𝗶𝗻𝗰𝗼𝗺𝗲 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗽𝗮𝗿𝘁 𝗶𝗻 𝘁𝗵𝗶𝘀 𝘀𝘂𝗿𝘃𝗲𝘆:
👉 https://fidp.co.uk/FIOpenSurvey-FP4/default.aspx?p=UK2407708501&IDTYPE=LIVE&CNT=826

By participating, you’ll help:
• Strengthen national immunisation strategies
• Align supply and demand
• Shape technical tools and regional manufacturing
• Support healthier vaccine markets for LMICs

Your voice matters.
Findings will be openly shared through public platforms and peer-reviewed publications—contributing to collective insight for impact in global health.

With thanks to Centre for Behavioural and Implementation Science Interventions (BISI) for the research collaboration, along with partners from NITAG Support Hub (NISH), UNICEF, World Health Organization, Every Breath Counts Coalition, Clinton Health Access Initiative, Inc., Murdoch Children's Research Institute (MCRI), Gavi, the Vaccine Alliance, JSI, Ipsos in the UK.

This study is led from the University of Geneva's Center for Vaccinology and received ethical clearance from the Committee for ethical research. It is funded by Gates Foundation.